Treatment for polycystic kidney disease shows promising results
Posted: 13 September 2019 | Rachael Harper (Drug Target Review) | No comments yet
A potential treatment for polycystic kidney disease has shown positive results in animal testing.


A potential treatment for polycystic kidney disease, which causes the kidneys to swell with multiple cysts, has shown promising results in animal testing, with approximately 50 percent reduction in kidney size in afflicted mice following treatment.


Polycystic kidney disease causes the kidneys to swell with multiple cysts. The new treatment showed a reduction of 50 percent kidney size in animal testing (credit: UT Southwestern).
The new treatment for autosomal dominant polycystic kidney disease (ADPDK) cooperatively developed at UT Southwestern, US and Regulus Therapeutics Inc, US showed no evidence of toxicity in animals or in human cell tests, according to the study. It is preferentially delivered to kidneys rather than the liver after being administered.
“We earlier showed that levels of a tiny RNA fragment called microRNA-17 are increased in models of ADPKD,” said Dr Vishal Patel, Associate Professor of Internal Medicine at UT Southwestern and senior author of the study. “MicroRNA-17 interferes with the normal function of other, beneficial RNAs, causing kidney cysts to grow. RGLS4326, as the new drug is called in development, works by blocking the harmful microRNA-17.”
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
Early Phase I clinical trials for the new treatment for polycystic kidney disease began last year. The US Food and Drug Administration (FDA) has asked for additional toxicity information from animal testing before human trials can move to the next step, Dr Patel said.
The study was published in Nature Communications.
Related topics
Clinical Trials, Drug Delivery, Drug Development, Drug Discovery, Formulation, RNAs
Related conditions
autosomal dominant polycystic kidney disease
Related organisations
Regulus Therapeutics Inc, US Food and Drug Administration (FDA), UT Southwestern
Related people
Dr Vishal Patel